Primary Hepatic EBV-DLBCL Lymphoma in the Setting of COVID-19 Infection

This case study describes an instance of primary hepatic diffuse large B cell lymphoma (DLBCL) in a patient who had prolonged coronavirus disease 2019 (COVID-19). DLBCL rarely presents as a primary hepatic mass. The 53-year-old man sought emergency care because of fatigue and weight loss. Diagnostic...

Full description

Saved in:
Bibliographic Details
Published inACG case reports journal Vol. 11; no. 2; p. e01276
Main Authors De Souza, Luisa Maria, Ismail, Mohamed, Elaskandrany, Menna-Allah, Fratella-Calabrese, Anthony, Grossman, I Robert
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer 01.02.2024
Subjects
Case Report
Liver
COVID-19
DLBCL
primary hepatic lymphoma
oncogenic features of COVID 19
Online AccessGet full text

Cover

More Information
Summary:This case study describes an instance of primary hepatic diffuse large B cell lymphoma (DLBCL) in a patient who had prolonged coronavirus disease 2019 (COVID-19). DLBCL rarely presents as a primary hepatic mass. The 53-year-old man sought emergency care because of fatigue and weight loss. Diagnostic tests showed mildly elevated liver enzymes and imaging pointed to several low-density liver lesions. A liver biopsy paired with immunohistochemical testing verified the DLBCL diagnosis. Notably, the patient had COVID-19 4 months before the liver-related symptoms. The link between COVID-19 and the emergence of solid tumor cancers is unclear, but this case underscores its potential significance and the need for further research. This report stresses the importance of recognizing and documenting instances where COVID-19 might influence the onset of solid tumor cancers, including primary hepatic DLBCL.
ISSN:2326-3253
2326-3253
DOI:10.14309/crj.0000000000001276